Literature DB >> 9636567

Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.

A Jain1, J Reyes, R Kashyap, S Rohal, T Cacclarelli, J McMichael, J Rakela, T E Starzl, J J Fung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636567      PMCID： PMC2974329          DOI： 10.1016/s0041-1345(98)00290-5

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

1.  The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation.

Authors:  J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner
Journal:  J Am Coll Surg       Date:  1996-08       Impact factor: 6.113

2.  One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

Authors:  A B Jain; J J Fung; S Todo; J Reyes; R Selby; W Irish; H Doyle; K Abu-Elmagd; A Casavilla; B Nour
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 3.  Randomised trialomania? The multicentre liver transplant trials of tacrolimus.

Authors:  T E Starzl; A Donner; M Eliasziw; L Stitt; P Meier; J J Fung; J P McMichael; S Todo
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

4.  De novo malignancy following liver transplantation: a single-center study.

Authors:  M Levy; L Backman; B Husberg; R Goldstein; R McMillan; J Gibbs; T A Gonwa; M Holman; G Klintmalm
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 5.  The problem of cancer in organ transplant recipients: an overview.

Authors:  I Penn
Journal:  Transplant Sci       Date:  1994-09

6.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

7.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.

Authors: 
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245
  7 in total
  6 in total

1.  Hepatic and intestinal transplantation at the University of Pittsburgh.

Authors:  K Abu-Elmagd; J Fung; J Reyes; A Rao; A Jain; G Mazariegos; W Marsh; J Madariaga; I Dvorchik; J Bueno; J Rogers; J McMichael; F Dodson; H Vargus; J Martin; A Slivka; V Balan; R Corry; J Rakela; N Murase; J Demetris; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1998

2.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

4.  Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.

Authors:  A B Jain; R Kashyap; J Rakela; T E Starzl; J J Fung
Journal:  Liver Transpl Surg       Date:  1999-03

5.  Burkitt s lymphoma variant of post-transplant lymphoproliferative disease (PTLD).

Authors:  Melissa A Pasquale; Debbie Weppler; Jon Smith; Michael Icardi; Alexandra Amador; Monica Gonzalez; Tomoaki Kato; Andreas Tzakis; Phillip Ruiz
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 6.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.